Gujarat Terce Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 18, 2025, 8:42 pm

Competitors of Gujarat Terce Laboratories Ltd

All Competitor Stocks of Gujarat Terce Laboratories Ltd

Quarterly Result

Last Updated: August 19, 2025, 2:10 pm

Below is a detailed analysis of the quarterly data for Gujarat Terce Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 10.85 Cr.. The value appears to be declining and may need further review. It has decreased from 12.32 Cr. (Mar 2025) to 10.85 Cr., marking a decrease of 1.47 Cr..
• For Expenses, as of Jun 2025, the value is 10.86 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 11.27 Cr. (Mar 2025) to 10.86 Cr., marking a decrease of 0.41 Cr..
• For Operating Profit, as of Jun 2025, the value is -0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 1.05 Cr. (Mar 2025) to -0.01 Cr., marking a decrease of 1.06 Cr..
• For OPM %, as of Jun 2025, the value is -0.09%. The value appears to be declining and may need further review. It has decreased from 8.52% (Mar 2025) to -0.09%, marking a decrease of 8.61%.
• For Other Income, as of Jun 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.09 Cr..
• For Interest, as of Jun 2025, the value is 0.05 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Mar 2025) to 0.05 Cr., marking a decrease of 0.02 Cr..
• For Depreciation, as of Jun 2025, the value is 0.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.10 Cr..
• For Profit before tax, as of Jun 2025, the value is -0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 0.97 Cr. (Mar 2025) to -0.07 Cr., marking a decrease of 1.04 Cr..
• For Tax %, as of Jun 2025, the value is -42.86%. The value appears to be improving (decreasing) as expected. It has decreased from 449.48% (Mar 2025) to -42.86%, marking a decrease of 492.34%.
• For Net Profit, as of Jun 2025, the value is -0.04 Cr.. The value appears strong and on an upward trend. It has increased from -3.39 Cr. (Mar 2025) to -0.04 Cr., marking an increase of 3.35 Cr..
• For EPS in Rs, as of Jun 2025, the value is -0.05. The value appears strong and on an upward trend. It has increased from -4.57 (Mar 2025) to -0.05, marking an increase of 4.52.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: August 23, 2025, 12:59 pm

Balance Sheet

Last Updated: August 11, 2025, 4:07 pm

Below is a detailed analysis of the balance sheet data for Gujarat Terce Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 7.42 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 7.42 Cr..
• For Reserves, as of Mar 2025, the value is -0.94 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -0.31 Cr. (Mar 2024) to -0.94 Cr., marking a decline of 0.63 Cr..
• For Borrowings, as of Mar 2025, the value is 0.94 Cr.. The value appears to be improving (decreasing). However, Reserves are negative, which is a major warning sign. It has decreased from 3.87 Cr. (Mar 2024) to 0.94 Cr., marking a decrease of 2.93 Cr..
• For Other Liabilities, as of Mar 2025, the value is 15.41 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 12.29 Cr. (Mar 2024) to 15.41 Cr., marking an increase of 3.12 Cr..
• For Total Liabilities, as of Mar 2025, the value is 22.83 Cr.. The value appears to be improving (decreasing). It has decreased from 23.27 Cr. (Mar 2024) to 22.83 Cr., marking a decrease of 0.44 Cr..
• For Fixed Assets, as of Mar 2025, the value is 3.65 Cr.. The value appears to be declining and may need further review. It has decreased from 3.69 Cr. (Mar 2024) to 3.65 Cr., marking a decrease of 0.04 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 0.52 Cr.. The value appears strong and on an upward trend. It has increased from 0.27 Cr. (Mar 2024) to 0.52 Cr., marking an increase of 0.25 Cr..
• For Other Assets, as of Mar 2025, the value is 18.66 Cr.. The value appears to be declining and may need further review. It has decreased from 19.31 Cr. (Mar 2024) to 18.66 Cr., marking a decrease of 0.65 Cr..
• For Total Assets, as of Mar 2025, the value is 22.83 Cr.. The value appears to be declining and may need further review. It has decreased from 23.27 Cr. (Mar 2024) to 22.83 Cr., marking a decrease of 0.44 Cr..

However, the Borrowings (0.94 Cr.) are higher than the Reserves (-0.94 Cr.), which may signal higher financial risk.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Gujarat Terce Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 5. It has decreased from 0.33 (Mar 24) to -1.32, marking a decrease of 1.65.
• For Diluted EPS (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 5. It has decreased from 0.33 (Mar 24) to -1.32, marking a decrease of 1.65.
• For Cash EPS (Rs.), as of Mar 25, the value is -0.80. This value is below the healthy minimum of 3. It has decreased from 0.82 (Mar 24) to -0.80, marking a decrease of 1.62.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.73. It has decreased from 9.58 (Mar 24) to 8.73, marking a decrease of 0.85.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 8.73. It has decreased from 9.58 (Mar 24) to 8.73, marking a decrease of 0.85.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 67.64. It has increased from 64.65 (Mar 24) to 67.64, marking an increase of 2.99.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 5.65. This value is within the healthy range. It has increased from 2.14 (Mar 24) to 5.65, marking an increase of 3.51.
• For PBIT / Share (Rs.), as of Mar 25, the value is 5.13. This value is within the healthy range. It has increased from 1.64 (Mar 24) to 5.13, marking an increase of 3.49.
• For PBT / Share (Rs.), as of Mar 25, the value is 4.57. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 4.57, marking an increase of 3.84.
• For Net Profit / Share (Rs.), as of Mar 25, the value is -1.32. This value is below the healthy minimum of 2. It has decreased from 0.32 (Mar 24) to -1.32, marking a decrease of 1.64.
• For PBDIT Margin (%), as of Mar 25, the value is 8.34. This value is below the healthy minimum of 10. It has increased from 3.30 (Mar 24) to 8.34, marking an increase of 5.04.
• For PBIT Margin (%), as of Mar 25, the value is 7.58. This value is below the healthy minimum of 10. It has increased from 2.54 (Mar 24) to 7.58, marking an increase of 5.04.
• For PBT Margin (%), as of Mar 25, the value is 6.75. This value is below the healthy minimum of 10. It has increased from 1.13 (Mar 24) to 6.75, marking an increase of 5.62.
• For Net Profit Margin (%), as of Mar 25, the value is -1.94. This value is below the healthy minimum of 5. It has decreased from 0.50 (Mar 24) to -1.94, marking a decrease of 2.44.
• For Return on Networth / Equity (%), as of Mar 25, the value is -15.10. This value is below the healthy minimum of 15. It has decreased from 3.42 (Mar 24) to -15.10, marking a decrease of 18.52.
• For Return on Capital Employeed (%), as of Mar 25, the value is 37.36. This value is within the healthy range. It has increased from 10.95 (Mar 24) to 37.36, marking an increase of 26.41.
• For Return On Assets (%), as of Mar 25, the value is -4.28. This value is below the healthy minimum of 5. It has decreased from 1.04 (Mar 24) to -4.28, marking a decrease of 5.32.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 0.2. It has decreased from 0.13 (Mar 24) to 0.04, marking a decrease of 0.09.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.14. This value is within the healthy range. It has decreased from 0.54 (Mar 24) to 0.14, marking a decrease of 0.40.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 2.18. It has increased from 1.85 (Mar 24) to 2.18, marking an increase of 0.33.
• For Current Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1.5. It has increased from 0.92 (Mar 24) to 0.95, marking an increase of 0.03.
• For Quick Ratio (X), as of Mar 25, the value is 0.66. This value is below the healthy minimum of 1. It has increased from 0.59 (Mar 24) to 0.66, marking an increase of 0.07.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 13.10. This value exceeds the healthy maximum of 8. It has increased from 1.80 (Mar 24) to 13.10, marking an increase of 11.30.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 10.09. This value is within the healthy range. It has increased from 2.35 (Mar 24) to 10.09, marking an increase of 7.74.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.36. This value is below the healthy minimum of 3. It has decreased from 1.36 (Mar 24) to -1.36, marking a decrease of 2.72.
• For Enterprise Value (Cr.), as of Mar 25, the value is 45.53. It has increased from 43.07 (Mar 24) to 45.53, marking an increase of 2.46.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.89 (Mar 24) to 0.90, marking an increase of 0.01.
• For EV / EBITDA (X), as of Mar 25, the value is 10.87. This value is within the healthy range. It has decreased from 27.12 (Mar 24) to 10.87, marking a decrease of 16.25.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.81 (Mar 24) to 0.90, marking an increase of 0.09.
• For Price / BV (X), as of Mar 25, the value is 7.00. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 7.00, marking an increase of 1.47.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.90. This value is below the healthy minimum of 1. It has increased from 0.81 (Mar 24) to 0.90, marking an increase of 0.09.
• For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to -0.02, marking a decrease of 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness